Koçyi?it, Ismail DorukTunali, MustafaÖzdemir, HakanKartal, YaseminSüer, Berkay Tolga2024-10-262024-10-2620122146-2852https://hdl.handle.net/20.500.12418/27220The therapeutic use of autologous platelet-rich fibrin constitutes a relatively new biotechnology that has been a breakthrough in the stimulation and acceleration of soft-tissue and bone healing. The efficiency of this process lies in the local and continuous delivery of a wide range of growth factors and proteins, mimicking the needs of the physiological wound healing and reparative tissue processes. Platelet-rich fibrin (PRF) belongs to a new generation of platelet concentrates, with simplified processing and without biochemical blood handling. This easy protocol allows the production of leukocyte and platelet-rich fibrin clots starting from autologous blood samples. PRF is used especially in clinical Periodontal and Oral and Maxillofacial Surgery applications. The significance of the PRF is gradually increasing.trinfo:eu-repo/semantics/closedAccessAutogenous fibrine; Growth hormone; PlateletArticle1532872792-s2.0-84866321473Q4